Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
FENNEC PHARMACEUTICALS INC.
Report date August 31, 2026 · Filed September 01, 2026
Section 16 reporting ended · disclosed 2026-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common sharesSEC Table I · non-derivative | Direct | 134,411 |
Reported balance
After 2026-08-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 2,778 · Balance 134,411 F1: Represents shares released from restriction from shares awarded 5/16/2024. |
| Common sharesSEC Table I · non-derivative | Direct | 124,411 |
Reported balance
After 2026-09-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-01 · Sale · Disposed 10,000 · Balance 124,411 F2: Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares released from restriction from shares awarded 5/16/2024.
F2: Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2023 Filed Nov 9, 2023 21:38 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 7,995 | $7.90 | $63,160.50 |
DisclosureSEC source: 0001415889-23-014958 · form4-11092023_091150.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,587 F2 · shares: Shares were the results of options granted on November 20, 2012, with a strike price of $1.05. Price of sold shares is an average. Read SEC document |
| November 08, 2023 Filed Nov 9, 2023 21:38 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 17,049 | $7.69 | $131,106.81 |
DisclosureSEC source: 0001415889-23-014958 · form4-11092023_091150.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,582 F1 · shares: Shares were the results of an option exercise on August 20, 2018, with a strike price of $1.44. Price of sold shares is an average. Read SEC document |
| November 03, 2023 Filed Nov 3, 2023 21:19 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionOption Contract · Derivative | 74,793 | $1.59 Strike: $1.59 | $118,920.87 |
DisclosureSEC source: 0001415889-23-014784 · form4-11032023_091158.xml · derivative · entry 2 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,596,040 Underlying: Options · 74,793 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents options granted on January 24, 2014, with a strike price of $1.59 and an expiration date of January 24, 2024. Read SEC document |
| November 03, 2023 Filed Nov 3, 2023 21:19 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 74,793 | $1.59 | $118,920.87 |
DisclosureSEC source: 0001415889-23-014784 · form4-11032023_091158.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with a strike price of $1.59 and an expiration date of January 24, 2024. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 20:23 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Share Unit · Derivative | 87,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005776 · form4-04032023_080404.xml · derivative · entry 2 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,670,833 Underlying: Common shares · 87,500 shares Expires 2033-03-31 F3 · security: On March 31, 2023, Rostislav Raykov was awarded restricted share units to receive 87,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F4 · derivative.exercise_date: 1/3 of the shares subject to this award shall be released from restriction as of March 31, 2024 (the "Vesting Commencement Date"). 1/24 of the award shall be released from restriction as of the last day of each month following the Vesting Commencement Date. As of March 31, 2026 and thereafter, 100% of the total number of shares subject to this award shall be released. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 20:23 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 175,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001415889-23-005776 · form4-04032023_080404.xml · derivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,583,333 Underlying: Common shares · 175,000 shares Expires 2033-03-31 F1 · security: On March 31, 2023, Rostislav Raykov was granted incentive stock options to purchase 175,000 shares of the issuers common shares pursuant to the issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of March 31, 2024 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of March 31, 2026 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| December 30, 2022 Filed Dec 30, 2022 22:09 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 8,400 | $9.61 | $80,753.40 |
DisclosureSEC source: 0001415889-22-013104 · form4-12302022_101203.xml · nonDerivative · entry 4 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,838 F4 · security: Shares were sold to pay taxes on share exercises on August 22, 2022 and September 9, 2022. Read SEC document |
| December 30, 2022 Filed Dec 30, 2022 22:09 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 1,600 | $9.66 | $15,453.76 |
DisclosureSEC source: 0001415889-22-013104 · form4-12302022_101203.xml · nonDerivative · entry 3 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,238 F3 · security: Shares were sold to pay taxes on share exercises on August 22, 2022 and September 9, 2022. Read SEC document |
| December 29, 2022 Filed Dec 30, 2022 22:09 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 5,000 | $9.65 | $48,250.00 |
DisclosureSEC source: 0001415889-22-013104 · form4-12302022_101203.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,838 F2 · security: Shares were sold to pay taxes on share exercises on August 22, 2022 and September 9, 2022. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 22:09 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 13,740 | $9.59 | $131,766.60 |
DisclosureSEC source: 0001415889-22-013104 · form4-12302022_101203.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,838 F1 · security: Shares were sold to pay taxes on share exercises on August 22, 2022 and September 9, 2022. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 13:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommons Shares · Derivative | 16,666 | $0.72 Strike: $0.72 | $11,999.52 |
DisclosureSEC source: 0001415889-22-009516 · form4-09122022_090902.xml · derivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,244 Underlying: options · 16,666 shares Expires 2023-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: 1. Represents options granted on August 23, 2013, with a $0.72 USD strike price and an expiration of August 23, 2023. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:34 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 50,000 | $1.05 Strike: $1.05 | $52,500.00 |
DisclosureSEC source: 0001104659-22-093721 · tm2224376-1_4seq1.xml · derivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,578 Underlying: options · 50,000 shares Expires 2022-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents options granted on November 20, 2012, with a $1.05 USD strike price and an expiration of November 20, 2022. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 22:47 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001104659-21-151821 · tm2135965-1_4seq1.xml · derivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2031-12-20 F1 · security: On December 20, 2021, Rostislav Raykov was granted an incentive stock option to purchase 300,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: Item vests 100% upon FDA approval of PEDMARKTM. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 15:53 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001104659-21-076218 · tm2118436-1_4seq1.xml · derivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 250,000 shares Expires 2031-06-02 F1 · security: On June 2, 2021, Rostislav Raykov was granted an incentive stock option to purchase 250,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of June 2, 2022 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of May 31, 2024 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 20:06 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon shares | 12,093 | $5.71 | $69,051.03 |
DisclosureSEC source: 0001104659-20-096097 · tm2028839d1_4.xml · nonDerivative · entry 5 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,578 F5 · price: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 323,861 shares from an August 18, 2010 grant of 323,961 shares. The price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $5.63 to $5.79 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 20:06 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon shares | 38,013 | $5.68 | $215,913.84 |
DisclosureSEC source: 0001104659-20-096097 · tm2028839d1_4.xml · nonDerivative · entry 4 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,671 F4 · price: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 323,861 shares from an August 18, 2010 grant of 323,961 shares. The price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $5.39 to $5.77 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:06 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon shares | 37,931 | $5.77 | $218,861.87 |
DisclosureSEC source: 0001104659-20-096097 · tm2028839d1_4.xml · nonDerivative · entry 3 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,684 F3 · price: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 323,861 shares from an August 18, 2010 grant of 323,961 shares. The price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $5.62 to $5.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:06 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon shares | 97,136 | $6.17 | $599,329.12 |
DisclosureSEC source: 0001104659-20-096097 · tm2028839d1_4.xml · nonDerivative · entry 2 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,615 F2 · price: Represents shares sold per a net exercise of shares to cover the proceeds necessary for the exercise of 323,861 shares at a USD$1.85 exercise price from the August 18, 2010 grant of 323,961 shares with expiration of August 18, 2020. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:06 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 323,961 | $1.85 | $599,327.85 |
DisclosureSEC source: 0001104659-20-096097 · tm2028839d1_4.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents options granted on August 18, 2010 with a CAD$ strike price of $2.43 CAD converted at 0.76 CAD/USD exchange ratio with an expiration of August 18, 2020. Read SEC document |
| May 15, 2020 Filed May 15, 2020 17:57 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001104659-20-062413 · tm2019938d2_4.xml · derivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 250,000 shares Expires 2030-05-15 F1 · security: On May 15, 2020, Rosty Raykov was granted an incentive stock option to purchase 250,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of May 15, 2021 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of May 15, 2023 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| April 04, 2019 Filed Apr 8, 2019 15:23 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001144204-19-018576 · tv518387_4.xml · derivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2026-04-04 F1 · security: On April 4, 2019, Rostislav Raykov was granted an incentive stock option to purchase 150,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of April 4, 2020 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of April 4, 2022 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 19:09 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Stock | 17,050 | $1.44 | $24,552.00 |
DisclosureSEC source: 0001144204-18-045760 · tv501431_4.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 23:46 UTC Amendment | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Stock | 17,050 | $1.44 | $24,552.00 |
DisclosureSEC source: 0001144204-18-045988 · tv501571_4a.xml · nonDerivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2018 Filed Feb 9, 2018 02:03 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001144204-18-006730 · tv485383_4.xml · derivative · entry 1 Raykov Rosty · CIK 0001468316 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2025-02-06 F1 · security: On February 6, 2018, Rosty Raykov was granted an incentive stock option to purchase 100,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of February 6, 2019 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of February 6, 2021 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.